Latigo Biotherapeutics, Inc. (LTGO) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $15.81M; Retained Earnings (Accumulated Deficit)USD $-291.89M; Stockholders' Equity Attributable to ParentUSD $-276.08M.
- 2026-03-31: Common Stock, Value, IssuedUSD (m); Additional Paid in CapitalUSD (m); Retained Earnings (Accumulated Deficit)USD (m); Stockholders' Equity Attributable to ParentUSD $-252.58M.
- 2025-12-31: Common Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $11.46M; Retained Earnings (Accumulated Deficit)USD $-243.13M; Stockholders' Equity Attributable to ParentUSD $-231.67M.
- 2025-06-30: Common Stock, Value, IssuedUSD (m); Additional Paid in CapitalUSD (m); Retained Earnings (Accumulated Deficit)USD (m); Stockholders' Equity Attributable to ParentUSD $-173.23M.
Latigo Biotherapeutics, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD |
|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $15.81M | $-291.89M | $-276.08M | 3 month · $2.14M |
| 2026-03-31 | (m) | (m) | (m) | $-252.58M | 3 month · $1.98M |
| 2025-12-31 | $0.00 | $11.46M | $-243.13M | $-231.67M | (m) |
| 2025-06-30 | (m) | (m) | (m) | $-173.23M | 3 month · $1.68M |
| 2025-03-31 | (m) | (m) | (m) | $-149.08M | 3 month · $1.48M |
| 2024-12-31 | (m) | (m) | (m) | $-129.60M | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |